News

May 24, 2024

Vinnova awards MedVasc a grant for a better understanding of reimbursement in the US

MedVasc has been awarded a grant of SEK 135,000 from Vinnova (Swedish Innovation Agency) to enhance the company’s understanding of the reimbursement landscape in the US. This support was secured through the Medtech4Health call 2024, aiming at strengthening small medtech companies through external competence. By the end of the…
May 3, 2024

SolutioTM featured on center stage at 2024 International Venous Conference

MedVasc anesthesia catheter SolutioTM gained attention during 2024 International Venous Conference as renowned KOL Dr. Lowell Kabnick gave a talk about next-generation venous devices:   …
May 3, 2024

SolutioTM featured in Venous News and Vascular specialist 

We are happy to announce that MedVasc anesthesia catheter SolutioTM has gained attention from important international newspapers within the industry. Please read and watch a short video of Founder Dr. Michael Åkesson in Venous News talking about the results from our first-in-man study: Vascular Specialist also wrote about the results from our…
May 3, 2024

Successful closing of SEK 5 million bridge-round

MedVasc has closed an investment round of 5 M SEK from existing investors.  The raised capital will be used to initiate manufacturing and final validation of FDA 510k pathway for the company’s anesthesia catheter SolutioTM. SolutioTM improves the golden standard methods for treatment of varicose veins and is expected…
May 3, 2024

Medvasc’s patent portfolio  granted in all prioritized jurisdictions

During 2023 MedVasc patent was granted in China, India, Canada, and Brazil. MedVasc’s patent portfolio is strengthened by the progression relating to the company’s medical device, the anesthesia catheter SolutioTM. SolutioTM minimizes the pain when performing the gold standard treatment methods for treating varicose veins and is expected to…

For press inquiries, please send an email

Subscribe to our newsletter

For more information on how we process your personal data please see our Privacy Notice